THOUSAND OAKS, Calif. and
2026世界杯直播赛程 FIFA 2026开球时间 SOUTH SAN FRANCISCO, Calif.,
FIFA 2026开球时间 FIFA 2026开球时间 Aug. 4, 2014 /PRNewswire/ --
世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 Amgen 观看比赛直播 (NASDAQ:AMGN) and its subsidiary,
世界杯比赛时间 2026世界杯直播赛程 FIFA 2026开球时间 Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated that the Phase 3 clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone 世界杯比赛时间 versus
观看比赛直播 FIFA 2026开球时间 Lenalidomide and Dexamethasone for 世界杯比赛时间 the treatment of PatIents with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival 世界杯比赛时间 (PFS). Patients treated
世界杯比赛时间 with Kyprolis® (carfilzomib) for Injection in combination with Revlimid® (lenalidomide) and low-dose dexamethasone (KRd) lived 世界杯比赛时间 significantly longer without
世界杯比赛时间 观看比赛直播 their disease worsening FIFA 2026开球时间 (median 26.3 months) compared to patients treated with Revlimid 观看比赛直播 and low-dose dexamethasone (Rd) (median 17.6 months) (HR=0.690, 95 percent 观看比赛直播 CI, 0.570, 0.834, p<0.0001).
世界杯比赛时间 While the data for overall survival, a secondary endpoint, are not yet mature, FIFA 2026开球时间 the analysis showed a trend in FIFA 2026开球时间 favor of KRd that did 世界杯比赛时间 not reach statistical significance.
The safety profile observed in FIFA 2026开球时间 this study FIFA 2026开球时间 is consistent with the current U.S. Kyprolis label, including the rate of cardiac events. Treatment discontinuation due to adverse events and on-study deaths were
世界杯比赛时间 comparable between the FIFA 2026开球时间 two arms. No new safety 世界杯比赛时间 signals were identified.
Results will be submitted for presentation at the upcoming 56th Annual Meeting of the
FIFA 2026开球时间 2026世界杯直播赛程 观看比赛直播 American Society of Hematology later this year.
"We FIFA 2026开球时间 are excited 世界杯比赛时间 about these clinical results and the positive prospects they 世界杯比赛时间 suggest for patients with multiple myeloma," 观看比赛直播 said
世界杯比赛时间 2026世界杯直播赛程 Robert A. Bradway, chairman and chief executive officer of
观看比赛直播 Amgen, adding, 2026世界杯直播赛程 FIFA 2026开球时间 "Our mission 观看比赛直播 at
观看比赛直播 世界杯比赛时间 世界杯比赛时间 FIFA 2026开球时间 Amgen is to serve patients by 观看比赛直播 FIFA 2026开球时间 advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline."
Bradway further explained, "Coupled with our recent U.S. regulatory submissions for ivabradine and talimogene laherparepvec and our upcoming regulatory submissions for evolocumab and blinatumomab, our pipeline
观看比赛直播 continues to show notable progress."
Results from the ASPIRE study will form the basis for regulatory submissions throughout the world beginning in the first half of 2015. In the U.S., the data may support the conversion of accelerated approval
世界杯比赛时间 FIFA 2026开球时间 2026世界杯直播赛程 to full approval and expand 世界杯比赛时间 the current indication.
"In the treatment of patients with multiple 世界杯比赛时间 myeloma, periods of remission become shorter following each treatment regimen, underscoring the need for new options. The 2026世界杯直播赛程 results of the ASPIRE study FIFA 2026开球时间 demonstrate
that Kyprolis can 观看比赛直播 significantly extend the time patients 世界杯比赛时间 live without their disease progressing," said
世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 Pablo J. Cagnoni, M.D., president,
Onyx Pharmaceuticals, Inc. "The ability of novel therapies to produce deep and durable responses may, one day, transform this uniformly fatal disease to one that is chronic and manageable."
Onyx conducted the ASPIRE study under a Special Protocol Assessment (SPA) from the
2026世界杯直播赛程 世界杯比赛时间 FIFA 2026开球时间 FIFA 2026开球时间 FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 U.S. Food and Drug Administration (
FDA) and has received Scientific Advice from the
世界杯比赛时间 European Medicines Agency (EMA) on the design and planned analysis of the study.
About ASPIRE
The international, randomized 观看比赛直播 Phase 3 ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of PatIents
世界杯比赛时间 with Relapsed Multiple MyEloma) trial evaluated Kyprolis in combination with lenalidomide and low-dose dexamethasone, versus lenalidomide and low-dose dexamethasone alone, in patients with
观看比赛直播 2026世界杯直播赛程 FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 relapsed multiple myeloma following treatment 世界杯比赛时间 with one to three prior regimens. The primary endpoint of the trial was progression-free survival, defined as the time from 观看比赛直播 treatment initiation to disease
2026世界杯直播赛程 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 progression or death. Secondary endpoints included overall survival, overall response rate, duration of response, disease control rate, health-related quality of life, and safety. Patients were randomized
FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 to receive Kyprolis (20mg/m2 on days 1 and 2 of cycle 1 only, then 27mg/m2 subsequently), in addition to a standard dosing schedule of lenalidomide 世界杯比赛时间 (25mg per day for 21 days on,
FIFA 2026开球时间 FIFA 2026开球时间 FIFA 2026开球时间 7 days off) and low-dose dexamethasone (40mg per week in 4 week cycles), versus lenalidomide and low-dose dexamethasone alone. The study randomized 792 patients at sites in
世界杯比赛时间 FIFA 2026开球时间 North America,
FIFA 2026开球时间 FIFA 2026开球时间 Europe, and
2026世界杯直播赛程 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 2026世界杯直播赛程 Israel.
About Multiple Myeloma
Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone 2026世界杯直播赛程 marrow. In the U.S., approximately 70,000
FIFA 2026开球时间 people are living with multiple myeloma and approximately 24,000 new cases are diagnosed annually.[1] Worldwide, 2026世界杯直播赛程 nearly 230,000 people are living with multiple myeloma and approximately 114,000 new cases
FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 are diagnosed annually.[2] In Europe, approximately 89,000 people are living with FIFA 2026开球时间 multiple myeloma, and approximately 39,000 new cases FIFA 2026开球时间 are diagnosed annually.[3]
About Kyprolis® (carfilzomib) for Injection
On
FIFA 2026开球时间 July 20, 2012, the
FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 FDA granted accelerated approval of 观看比赛直播 Kyprolis® (carfilzomib) for Injection for the treatment of patients with multiple 观看比赛直播 myeloma who have received at least two prior therapies including
FIFA 2026开球时间 bortezomib and an immunomodulatory agent (IMiD), and have demonstrated disease 世界杯比赛时间 progression on or 世界杯比赛时间 within 60 days of completion of the last therapy. Approval was based on FIFA 2026开球时间 response rate. Clinical benefit,
观看比赛直播 2026世界杯直播赛程 世界杯比赛时间 世界杯比赛时间 2026世界杯直播赛程 such as improvement in survival or symptoms, has not been verified.
Kyprolis is marketed in 世界杯比赛时间 the U.S. by
FIFA 2026开球时间 FIFA 2026开球时间 2026世界杯直播赛程 世界杯比赛时间 世界杯比赛时间 世界杯比赛时间 世界杯比赛时间 Onyx Pharmaceuticals, Inc., an
Amgen subsidiary.
Important Safety Information 观看比赛直播 Regarding Kyprolis® (carfilzomib) for Injection
Safety data have been evaluated in 526 FIFA 2026开球时间 patients with relapsed and/or refractory multiple myeloma who
FIFA 2026开球时间 世界杯比赛时间 received single-agent Kyprolis. There were 37 deaths in the Phase 2 studies, or 7% of patients. The most common causes of death, other than 观看比赛直播 disease progression, were cardiac (5 2026世界杯直播赛程 patients), end-organ 观看比赛直播 failure
观看比赛直播 观看比赛直播 (4 patients), and infection FIFA 2026开球时间 (4 patients). Important 世界杯比赛时间 warnings and precautions include cardiac arrest, congestive heart failure, myocardial 2026世界杯直播赛程 ischemia; 世界杯比赛时间 pulmonary hypertension, pulmonary complications, infusion
reactions, tumor lysis syndrome, thrombocytopenia, hepatic toxicity and embryo-fetal toxicity.
Death due to cardiac arrest has occurred within a day of Kyprolis administration. Patients with New York Heart Association Class III and IV heart FIFA 2026开球时间 failure, myocardial infarction in the preceding 6 months,
世界杯比赛时间 and conduction abnormalities uncontrolled by medications were not eligible for the clinical trials. These patients 2026世界杯直播赛程 世界杯比赛时间 may be at greater risk 观看比赛直播 FIFA 2026开球时间 for cardiac complications.
Pulmonary arterial hypertension (PAH) was reported in 2% of patients 世界杯比赛时间 treated with Kyprolis and was Grade 3 or greater in less than 1% of patients. Dyspnea was reported in 35% of patients enrolled in clinical
FIFA 2026开球时间 trials. Grade 3 dyspnea occurred in 5%; no Grade 4 events, and 1 death (Grade 5) was reported.
Infusion reactions, characterized by a spectrum of systemic symptoms including fever, chills, arthralgia, myalgia, facial FIFA 2026开球时间 flushing, facial 世界杯比赛时间 edema, vomiting, weakness, shortness of breath, hypotension, syncope,
FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 chest tightness, or angina can occur immediately following or up to 24 hours after administration of Kyprolis. Administration of dexamethasone prior to Kyprolis reduces the incidence and severity of
观看比赛直播 reactions. Tumor lysis syndrome (TLS) occurred following Kyprolis administration in < 1% of patients. Patients with multiple myeloma and a high tumor burden should be considered 2026世界杯直播赛程 to be at greater 观看比赛直播 risk
for TLS.
Thrombocytopenia following Kyprolis FIFA 2026开球时间 administration resulted in a dose reduction in 1% of 2026世界杯直播赛程 FIFA 2026开球时间 patients 2026世界杯直播赛程 and discontinuation of treatment with Kyprolis FIFA 2026开球时间 in < 1% of patients.
Cases of hepatic failure, including fatal cases, have been reported (< 1%). Kyprolis can cause elevations of serum transaminases and bilirubin.
There are no adequate and well-controlled studies in pregnant women using Kyprolis. Females of reproductive potential should be advised to avoid becoming pregnant while being treated with Kyprolis.
The 观看比赛直播 most common serious adverse reactions were pneumonia, acute FIFA 2026开球时间 2026世界杯直播赛程 renal failure, pyrexia, and congestive heart failure. The most common adverse reactions (incidence 世界杯比赛时间 of 30% or greater) observed in clinical
2026世界杯直播赛程 FIFA 2026开球时间 观看比赛直播 FIFA 2026开球时间 trials of FIFA 2026开球时间 patients with multiple myeloma were fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, 世界杯比赛时间 and pyrexia. Serious adverse reactions were reported in 45% of patients.
2026世界杯直播赛程 Full prescribing information is available at http://www.kyprolis.com/.
世界杯比赛时间 世界杯比赛时间
About Amgen
Amgen is committed FIFA 2026开球时间 to unlocking the potential 世界杯比赛时间 of biology for patients 观看比赛直播 suffering from serious illnesses by discovering, developing,
观看比赛直播 manufacturing and delivering innovative human therapeutics. This approach begins by using tools 世界杯比赛时间 like advanced human genetics 2026世界杯直播赛程 to unravel the complexities FIFA 2026开球时间 of disease and understand the fundamentals of
FIFA 2026开球时间 FIFA 2026开球时间 human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health 观看比赛直播 outcomes and dramatically improve people's lives. A 2026世界杯直播赛程 biotechnology
FIFA 2026开球时间 观看比赛直播 观看比赛直播 pioneer since 世界杯比赛时间 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and 世界杯比赛时间 is developing a pipeline of medicines with breakaway
世界杯比赛时间 2026世界杯直播赛程 世界杯比赛时间 potential.
2026世界杯直播赛程 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间
观看比赛直播 For more information, visit http://www.amgen.com/ and follow us on www.twitter.com/amgen.
观看比赛直播
About Onyx Pharmaceuticals, Inc.
Based FIFA 2026开球时间 in
FIFA 2026开球时间 2026世界杯直播赛程 观看比赛直播 South San Francisco, California,
世界杯比赛时间 2026世界杯直播赛程 世界杯比赛时间 Onyx Pharmaceuticals, Inc., an
2026世界杯直播赛程 FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 Amgen subsidiary, is a global biopharmaceutical company engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. The company is focused
世界杯比赛时间 世界杯比赛时间 FIFA 2026开球时间 on developing novel medicines that target key molecular pathways. For more information about Onyx, visit the company's website at http://www.onyx.com/.
FIFA 2026开球时间 FIFA 2026开球时间 Onyx Pharmaceuticals is on Twitter. Sign up FIFA 2026开球时间 to follow our Twitter 观看比赛直播 feed @OnyxPharm 观看比赛直播 at http://twitter.com/OnyxPharm.
世界杯比赛时间
REVLIMID® is a registered trademark of
FIFA 2026开球时间 Celgene Corporation.
Forward-Looking Statements
This news 世界杯比赛时间 release contains forward-looking statements that are based on the current expectations and beliefs of
2026世界杯直播赛程 世界杯比赛时间 FIFA 2026开球时间 Amgen Inc. FIFA 2026开球时间 and its FIFA 2026开球时间 subsidiaries (
观看比赛直播 世界杯比赛时间 世界杯比赛时间 Amgen) and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical
世界杯比赛时间 FIFA 2026开球时间 fact, are statements that FIFA 2026开球时间 could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, FIFA 2026开球时间 expected legal, arbitration,
世界杯比赛时间 FIFA 2026开球时间 political, regulatory or clinical results or practices, FIFA 2026开球时间 customer and prescriber patterns or practices, reimbursement 观看比赛直播 activities and outcomes and other such estimates and results. Forward-looking statements
世界杯比赛时间 观看比赛直播 世界杯比赛时间 involve significant risks and uncertainties, including those discussed below and more fully described in the
世界杯比赛时间 Securities and Exchange Commission (
观看比赛直播 SEC) reports filed by
2026世界杯直播赛程 2026世界杯直播赛程 Amgen Inc., including
FIFA 2026开球时间 观看比赛直播 FIFA 2026开球时间 FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 Amgen Inc.'s 2026世界杯直播赛程 世界杯比赛时间 most recent annual report on Form FIFA 2026开球时间 10-K and any subsequent periodic reports on Form 10-Q and Form 8-K. Please refer to
世界杯比赛时间 2026世界杯直播赛程 Amgen Inc.'s most recent Forms 10-K, 10-Q and 8-K for additional information on 观看比赛直播 FIFA 2026开球时间 the uncertainties and risk factors related to
观看比赛直播 Amgen's business. Unless otherwise noted,
观看比赛直播 观看比赛直播 2026世界杯直播赛程 2026世界杯直播赛程 观看比赛直播 Amgen is providing this information as of
FIFA 2026开球时间 FIFA 2026开球时间 Aug. 4, 2014 and expressly disclaims any duty to update information contained in this news release.
No forward-looking statement 观看比赛直播 can be guaranteed and actual results 2026世界杯直播赛程 may differ material from those
世界杯比赛时间 观看比赛直播 FIFA 2026开球时间 2026世界杯直播赛程 Amgen projects. Discovery or identification 观看比赛直播 of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept 观看比赛直播 to product is uncertain;
FIFA 2026开球时间 consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical
世界杯比赛时间 FIFA 2026开球时间 FIFA 2026开球时间 FIFA 2026开球时间 results do not FIFA 2026开球时间 guarantee safe and effective performance of product 世界杯比赛时间 candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, FIFA 2026开球时间 even adequately modeled by computer or cell
世界杯比赛时间 2026世界杯直播赛程 culture systems or animal models. The length of 观看比赛直播 time that it takes for
世界杯比赛时间 Amgen and its partners to FIFA 2026开球时间 complete clinical trials and obtain regulatory approval 观看比赛直播 for product marketing has in the past varied and
FIFA 2026开球时间 世界杯比赛时间 2026世界杯直播赛程 Amgen expects 世界杯比赛时间 similar variability in the future.
2026世界杯直播赛程 Amgen develops product candidates internally and FIFA 2026开球时间 through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes
观看比赛直播 2026世界杯直播赛程 观看比赛直播 between the parties or may prove to be not as effective or as safe as
FIFA 2026开球时间 世界杯比赛时间 世界杯比赛时间 FIFA 2026开球时间 Amgen may have believed at the time of entering into 观看比赛直播 such relationship. Also,
世界杯比赛时间 Amgen or others could identify safety, side effects or manufacturing problems with
FIFA 2026开球时间 2026世界杯直播赛程 Amgen's products after they are on the market.
世界杯比赛时间 Amgen's business may be impacted by government FIFA 2026开球时间 investigations, litigation and product liability claims. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between
观看比赛直播 世界杯比赛时间 观看比赛直播 Amgen and the U.S. government,
世界杯比赛时间 2026世界杯直播赛程 世界杯比赛时间 观看比赛直播 Amgen could become subject to significant sanctions.
世界杯比赛时间 Amgen depends on third parties for a significant portion of its manufacturing capacity for the supply of certain of its current 2026世界杯直播赛程 and future products and limits on FIFA 2026开球时间 世界杯比赛时间 supply may constrain sales of certain
2026世界杯直播赛程 2026世界杯直播赛程 of its current FIFA 2026开球时间 products and product candidate development.
In addition, sales of
FIFA 2026开球时间 2026世界杯直播赛程 Amgen's products (including products of
观看比赛直播 FIFA 2026开球时间 世界杯比赛时间 观看比赛直播 Amgen's wholly-owned subsidiaries) 2026世界杯直播赛程 are affected by the reimbursement policies imposed by third-party payers, including governments, 世界杯比赛时间 private insurance plans and managed care providers and 世界杯比赛时间 may 观看比赛直播 be
2026世界杯直播赛程 2026世界杯直播赛程 FIFA 观看比赛直播 2026开球时间 affected by 观看比赛直播 regulatory, clinical and guideline developments and domestic and international trends 世界杯比赛时间 toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical
FIFA 2026开球时间 FIFA 2026开球时间 pricing FIFA 2026开球时间 and reimbursement. Government and others' regulations and FIFA 2026开球时间 reimbursement policies may affect the development, usage and pricing of
Amgen's products. In addition,
Amgen competes with other 世界杯比赛时间 companies with respect to some of its marketed products as well 世界杯比赛时间 as for the discovery and 世界杯比赛时间 development of new products.
观看比赛直播 世界杯比赛时间 2026世界杯直播赛程 2026世界杯直播赛程 2026世界杯直播赛程 世界杯比赛时间 Amgen believes that some of its newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed.
世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 Amgen's products may compete against FIFA 2026开球时间 products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with its products.
观看比赛直播 In addition, while
观看比赛直播 FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 Amgen and its partners routinely FIFA 2026开球时间 obtain patents for their products 2026世界杯直播赛程 and technology, the protection of
2026世界杯直播赛程 FIFA 2026开球时间 FIFA 2026开球时间 2026世界杯直播赛程 Amgen's 世界杯比赛时间 products offered by patents and patent applications may be challenged, invalidated or circumvented by its competitors and there can be no guarantee of
2026世界杯直播赛程 Amgen's or its partners' ability to obtain or maintain patent protection for
FIFA 2026开球时间 Amgen's products or product candidates.
FIFA 2026开球时间 Amgen cannot guarantee that it will be able to produce commercially successful products or maintain the commercial success 世界杯比赛时间 of its existing products.
FIFA 2026开球时间 FIFA 2026开球时间 Amgen's stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of its products or product candidates. Further, the discovery of significant
FIFA 2026开球时间 世界杯比赛时间 problems with a FIFA 2026开球时间 product similar to one of
Amgen's products that implicate an entire FIFA 2026开球时间 class of products FIFA 2026开球时间 could have FIFA 2026开球时间 a material adverse effect on sales of the affected products and on
2026世界杯直播赛程 世界杯比赛时间 世界杯比赛时间 FIFA 2026开球时间 FIFA 2026开球时间 Amgen's business and results of operations.
世界杯比赛时间 世界杯比赛时间 Amgen's efforts to integrate the operations of companies it has acquired may FIFA 2026开球时间 not be successful. Cost saving initiatives may result in
世界杯比赛时间 世界杯比赛时间 FIFA 2026开球时间 世界杯比赛时间 观看比赛直播 Amgen incurring impairment or other related charges on its FIFA 2026开球时间 assets.
2026世界杯直播赛程 世界杯比赛时间 Amgen may 2026世界杯直播赛程 世界杯比赛时间 experience difficulties, delays or unexpected costs and not achieve anticipated cost savings from its recently announced restructuring plans.
观看比赛直播 Amgen's business performance could affect or limit the FIFA 2026开球时间 ability of
观看比赛直播 Amgen's Board of Directors to declare a dividend or their ability to pay a dividend FIFA 2026开球时间 or repurchase
世界杯比赛时间 FIFA 2026开球时间 FIFA 2026开球时间 2026世界杯直播赛程 世界杯比赛时间 观看比赛直播 Amgen common stock.
The scientific information discussed in 世界杯比赛时间 this news release relating to new indications for
世界杯比赛时间 Amgen's products is preliminary and investigative and is not part of the labeling approved by the
FIFA 2026开球时间 U.S. Food and 世界杯比赛时间 Drug Administration (
世界杯比赛时间 FDA) for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be 观看比赛直播 drawn regarding the safety or effectiveness
世界杯比赛时间 of the products for these uses.
CONTACT:
世界杯比赛时间 FIFA 2026开球时间 Amgen,
2026世界杯直播赛程 世界杯比赛时间 Thousand Oaks
Kristen Davis, 805-447-3008 (
世界杯比赛时间 Amgen media)
Danielle Bertrand, 650-266-2114 (Onyx media)
Arvind Sood, 2026世界杯直播赛程 805-447-1060 (investors)
观看比赛直播 Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
观看比赛直播 观看比赛直播 2026世界杯直播赛程 FIFA 2026开球时间 世界杯比赛时间 [1]
2026世界杯直播赛程 观看比赛直播 National Cancer Institute. SEER Stat Fact Sheets: Myeloma. Available at 世界杯比赛时间 http://seer.cancer.gov/statfacts/html/mulmy.html.
观看比赛直播 2026世界杯直播赛程
[2]
世界杯比赛时间 世界杯比赛时间 International Agency for Research on Cancer, GLOBOCAN 2012 database. Available at http://globocan.iarc.fr/.
[3]Cancer
世界杯比赛时间 观看比赛直播 2026世界杯直播赛程 观看比赛直播 观看比赛直播 Research UK. "Myeloma Incidence Statistics." Available at: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/incidence/uk-multiple-myeloma-incidence-statistics#europeandworldwide.
FIFA 2026开球时间 FIFA 2026开球时间 世界杯比赛时间
SOURCE
FIFA 2026开球时间 世界杯比赛时间 FIFA 2026开球时间 Amgen
